the risk of bone loss in women using Depo-Provera
A new warning highlights the risk of bone loss in women using Depo-Provera.
It can decrease bone density by one to two percent per year.
This bone loss may be only partially reversible...and continues the longer the drug is used.
Table of Contents
- concerns over potentially harmful drugs
- flecainide (Tambocor) or propafenone (Rythmol) written "take as needed for atrial fibrillation"
- Reps will be saying that amlodipine (Norvasc) reduces the risk of cardiovascular events
- Humira, a new biologic therapy for rheumatoid arthritis
- Light therapy is often as effective as antidepressants for seasonal affective disorder (SAD)
- Ritalin, Adderall, and other stimulants to enhance test scores
- Reps will be touting evidence that suggests carvedilol is better than metoprolol for diabetes patients
- Tysabri (tie-SAB-ree), the latest investigational treatment for multiple sclerosis (MS)
- Aricept and other cholinesterase inhibitors for patients with multiple sclerosis
- Cold-fX is getting a LOT of attention for treating and preventing colds
- Is it legal to have melatonin on the shelves in Canada
- the risk of bone loss in women using Depo-Provera
- whether testosterone is appropriate for treating sexual dysfunction in women
- More women with EARLY breast cancer will be treated with an aromatase inhibitor
- treatment for gonorrhea has changed
- malaria prophylaxis for travellers to the Dominican Republic
- End of year is a good time to reflect on trustworthy drug information that is relevant to practice.